Centrally Acting Anti-Obesity Agents

[1]  Ruo Xu,et al.  Bicyclic[4.1.0]heptanes as phenyl replacements for melanin concentrating hormone receptor antagonists. , 2006, Bioorganic & medicinal chemistry.

[2]  J. Tanaka,et al.  Pharmacological Characterization and Feeding-Suppressive Property of FMS586 [3-(5,6,7,8-Tetrahydro-9-isopropyl-carbazol-3-yl)-1-methyl-1-(2-pyridin-4-yl-ethyl)-urea Hydrochloride], a Novel, Selective, and Orally Active Antagonist for Neuropeptide Y Y5 Receptor , 2006, Journal of Pharmacology and Experimental Therapeutics.

[3]  A. Hancock.  The challenge of drug discovery of a GPCR target: analysis of preclinical pharmacology of histamine H3 antagonists/inverse agonists. , 2006, Biochemical pharmacology.

[4]  J. Holenz,et al.  Medicinal chemistry strategies to 5-HT(6) receptor ligands as potential cognitive enhancers and antiobesity agents. , 2006, Drug discovery today.

[5]  H. Sham,et al.  Optimization of 2,4-diaminopyrimidines as GHS-R antagonists: side chain exploration. , 2006, Bioorganic & medicinal chemistry letters.

[6]  R. Adan.  Constitutive receptor activity series: endogenous inverse agonists and constitutive receptor activity in the melanocortin system. , 2006, Trends in pharmacological sciences.

[7]  G. Fox,et al.  Histamine H3 receptor antagonists: preclinical promise for treating obesity and cognitive disorders. , 2006, Molecular interventions.

[8]  J. Knittel,et al.  Neuropeptide Y (NPY) Y4 receptor selective agonists based on NPY(32-36): development of an anorectic Y4 receptor selective agonist with picomolar affinity. , 2006, Journal of medicinal chemistry.

[9]  Mark D. McBriar,et al.  Effects of a selective melanin-concentrating hormone 1 receptor antagonist on food intake and energy homeostasis in diet-induced obese mice. , 2006, European journal of pharmacology.

[10]  G. Hervieu,et al.  Further insights into the neurobiology of melanin-concentrating hormone in energy and mood balances , 2006, Expert opinion on therapeutic targets.

[11]  E. Bush,et al.  2,4-diaminopyrimidine derivatives as potent growth hormone secretagogue receptor antagonists. , 2006, Journal of medicinal chemistry.

[12]  Ju Gao,et al.  Screening for cardiovascular safety: a structure-activity approach for guiding lead selection of melanin concentrating hormone receptor 1 antagonists. , 2006, Journal of medicinal chemistry.

[13]  W. Greenlee,et al.  Discovery of orally efficacious melanin-concentrating hormone receptor-1 antagonists as antiobesity agents. Synthesis, SAR, and biological evaluation of bicyclo[3.1.0]hexyl ureas. , 2006, Journal of medicinal chemistry.

[14]  P. Mattei,et al.  Synthesis and biological evaluation of novel hexahydro-pyrido[3',2':4,5]pyrrolo[1,2-a]pyrazines as potent and selective 5-HT(2C) receptor agonists. , 2006, Bioorganic & medicinal chemistry letters.

[15]  Brian M. Smith,et al.  The potential use of selective 5-HT2C agonists in treating obesity , 2006, Expert Opinion on Investigational Drugs.

[16]  S. Peluso,et al.  Mapping the binding site of melanocortin 4 receptor agonists: a hydrophobic pocket formed by I3.28(125), I3.32(129), and I7.42(291) is critical for receptor activation. , 2006, Journal of medicinal chemistry.

[17]  D. Macintyre,et al.  Synthesis of functionalized 1,8-naphthyridinones and their evaluation as novel, orally active CB1 receptor inverse agonists. , 2006, Bioorganic & medicinal chemistry letters.

[18]  D. Scott,et al.  New bicyclic cannabinoid receptor-1 (CB1-R) antagonists. , 2006, Bioorganic & medicinal chemistry letters.

[19]  C. Haskell-Luevano.  Physiology and chemistry of the melanocortin pathway , 2006, Peptides.

[20]  B. Matuszewski,et al.  Determination of a Selective Neuropeptide Y5 Receptor Antagonist in Human Plasma and Urine by HPLC with Tandem Mass Spectrometric Detection , 2006 .

[21]  H. H. Refsgaard,et al.  Influence of a selective histamine H3 receptor antagonist on hypothalamic neural activity, food intake and body weight , 2005, International Journal of Obesity.

[22]  J. Després,et al.  Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. , 2005, The New England journal of medicine.

[23]  R. L. Clark,et al.  Peptide YY(3-36) inhibits morning, but not evening, food intake and decreases body weight in rhesus macaques. , 2005, Diabetes.

[24]  C. Haskell-Luevano,et al.  A review of melanocortin receptor small molecule ligands , 2005, Peptides.

[25]  N. C. Ray,et al.  Recent developments in the discovery of MCH-1R antagonists for the treatment of obesity – an update , 2005 .

[26]  M. Siegel,et al.  SAR and biological evaluation of novel trans-3,4-dimethyl-4-arylpiperidine derivatives as opioid antagonists. , 2005, Bioorganic & medicinal chemistry letters.

[27]  Thomas Fey,et al.  Discovery and characterization of aminopiperidinecoumarin melanin concentrating hormone receptor 1 antagonists. , 2005, Journal of medicinal chemistry.

[28]  J. Metzger,et al.  Discovery and activity of (1R,4S,6R)-N-[(1R)-2-[4-cyclohexyl-4-[[(1,1-dimethylethyl)amino]carbonyl]-1-piperidinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]-2-methyl-2-azabicyclo[2.2.2]octane-6-carboxamide (3, RY764), a potent and selective melanocortin subtype-4 receptor agonist. , 2005, Bioorganic & Medicinal Chemistry Letters.

[29]  A. Meneses,et al.  Oral administration of the 5-HT6 receptor antagonists SB-357134 and SB-399885 improves memory formation in an autoshaping learning task , 2005, Pharmacology Biochemistry and Behavior.

[30]  S. O’Rahilly,et al.  Melanocortin receptors and energy homeostasis , 2005 .

[31]  G. Muccioli,et al.  Current knowledge on the antagonists and inverse agonists of cannabinoid receptors. , 2005, Current medicinal chemistry.

[32]  J. Lange,et al.  Keynote review: Medicinal chemistry strategies to CB1 cannabinoid receptor antagonists. , 2005, Drug discovery today.

[33]  K. Toshinai,et al.  The role of the vagal nerve in peripheral PYY3-36-induced feeding reduction in rats. , 2005, Endocrinology.

[34]  B. Harrison,et al.  WAY-163909 [(7bR, 10aR)-1,2,3,4,8,9,10,10a-Octahydro-7bH-cyclopenta-[b][1,4]diazepino[6,7,1hi]indole], a Novel 5-Hydroxytryptamine 2C Receptor-Selective Agonist with Anorectic Activity , 2005, Journal of Pharmacology and Experimental Therapeutics.

[35]  L. V. D. van der Ploeg,et al.  2-Piperazinecarboxamides as potent and selective melanocortin subtype-4 receptor agonists. , 2005, Bioorganic & medicinal chemistry letters.

[36]  Jyoti R. Patel,et al.  Structure-activity relationship studies on tetralin carboxamide growth hormone secretagogue receptor antagonists. , 2005, Bioorganic & medicinal chemistry letters.

[37]  E. Bush,et al.  Antiobesity evaluation of histamine H3 receptor (H3R) antagonist analogs of A-331440 with improved safety and efficacy , 2005, Inflammation Research.

[38]  R. Batterham,et al.  Peptide YY: a potential therapy for obesity. , 2005, Current drug targets.

[39]  H. Sham,et al.  Synthesis and structure-activity relationships of isoxazole carboxamides as growth hormone secretagogue receptor antagonists. , 2005, Bioorganic & medicinal chemistry letters.

[40]  D. Porte,et al.  Diabetes, Obesity, and the Brain , 2005, Science.

[41]  T. Baillie,et al.  Metabolic activation of a 1,3-disubstituted piperazine derivative: evidence for a novel ring contraction to an imidazoline. , 2005, Chemical research in toxicology.

[42]  H. Sham,et al.  Novel isoxazole carboxamides as growth hormone secretagogue receptor (GHS-R) antagonists. , 2004, Bioorganic & medicinal chemistry letters.

[43]  Mark D. McBriar,et al.  Therapeutic potential of melanin-concentrating hormone-1 receptor antagonists for the treatment of obesity , 2004, Expert opinion on investigational drugs.

[44]  R. Bodnar.  Endogenous opioids and feeding behavior: a 30-year historical perspective , 2004, Peptides.

[45]  J. Fauchère,et al.  A potent and selective NPY Y5 antagonist reduces food intake but not through blockade of the NPY Y5 receptor , 2004, International Journal of Obesity.

[46]  J. Gerberding,et al.  Actual causes of death in the United States, 2000. , 2004, JAMA.

[47]  T. Schwartz,et al.  Constitutive ghrelin receptor activity as a signaling set-point in appetite regulation. , 2004, Trends in pharmacological sciences.

[48]  Andrew Browning,et al.  Recent developments in the discovery of melanin-concentrating hormone antagonists: novel antiobesity agents , 2004 .

[49]  G. Frost,et al.  Pancreatic polypeptide reduces appetite and food intake in humans. , 2003, The Journal of clinical endocrinology and metabolism.

[50]  G. Kennett,et al.  Oral administration of the 5-HT2C receptor agonist, mCPP, reduces body weight gain in rats over 28 days as a result of maintained hypophagia , 2003, Psychopharmacology.

[51]  S. Black,et al.  Antiobesity effects of chronic cannabinoid CB1 receptor antagonist treatment in diet-induced obese mice. , 2003, European journal of pharmacology.

[52]  P. Soubrié,et al.  Anti-obesity effect of SR141716, a CB1 receptor antagonist, in diet-induced obese mice. , 2003, American journal of physiology. Regulatory, integrative and comparative physiology.

[53]  H. Kotani,et al.  Targeted disruption of H3 receptors results in changes in brain histamine tone leading to an obese phenotype. , 2002, The Journal of clinical investigation.

[54]  D. Lynch,et al.  N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (SR141716A) interaction with LYS 3.28(192) is crucial for its inverse agonism at the cannabinoid CB1 receptor. , 2002, Molecular Pharmacology.

[55]  S. Boyer,et al.  Selective antagonism of the NPY Y5 receptor does not have a major effect on feeding in rats. , 2002, Diabetes.

[56]  M. Herkenham,et al.  International Union of Pharmacology. XXVII. Classification of Cannabinoid Receptors , 2002, Pharmacological Reviews.

[57]  A. Genazzani,et al.  Effect of long-term naltrexone treatment on endocrine profile, clinical features, and insulin sensitivity in obese women with polycystic ovary syndrome. , 2002, Fertility and sterility.

[58]  William J Welsh,et al.  Molecular interaction of the antagonist N-(piperidin-1-yl)-5-(4-chlorophenyl)-1- (2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide with the CB1 cannabinoid receptor. , 2002, Journal of medicinal chemistry.

[59]  G. Frost,et al.  Ghrelin enhances appetite and increases food intake in humans. , 2001, The Journal of clinical endocrinology and metabolism.

[60]  R. Batterham,et al.  Ghrelin causes hyperphagia and obesity in rats. , 2001, Diabetes.

[61]  A. Sleight,et al.  A role for 5-ht6 receptors in retention of spatial learning in the Morris water maze , 2001, Neuropharmacology.

[62]  R. Palmiter,et al.  Leptin-regulated endocannabinoids are involved in maintaining food intake , 2001, Nature.

[63]  Z. Vogel,et al.  2-Arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[64]  D. Macneil,et al.  L-152,804: orally active and selective neuropeptide Y Y5 receptor antagonist. , 2000, Biochemical and biophysical research communications.

[65]  M. Nakazato,et al.  Ghrelin is a growth-hormone-releasing acylated peptide from stomach , 1999, Nature.

[66]  L. Tecott,et al.  Reduced satiating effect of d-fenfluramine in serotonin 5-HT2C receptor mutant mice , 1999, Psychopharmacology.

[67]  T. Kirkham,et al.  Anandamide induces overeating: mediation by central cannabinoid (CB1) receptors , 1999, Psychopharmacology.

[68]  P S Kalra,et al.  Interacting appetite-regulating pathways in the hypothalamic regulation of body weight. , 1999, Endocrine reviews.

[69]  G. Gessa,et al.  Appetite suppression and weight loss after the cannabinoid antagonist SR 141716. , 1998, Life sciences.

[70]  A. Kelley,et al.  Intake of high-fat food is selectively enhanced by mu opioid receptor stimulation within the nucleus accumbens. , 1998, The Journal of pharmacology and experimental therapeutics.

[71]  R. Bodnar.  Recent advances in the understanding of the effects of opioid agents on feeding and appetite. , 1998, Expert opinion on investigational drugs.

[72]  M. Yeomans,et al.  Effects of Naltrexone on Food Intake and Changes in Subjective Appetite During Eating: Evidence for Opioid Involvement in the Appetizer Effect , 1997, Physiology & Behavior.

[73]  David Julius,et al.  Eating disorder and epilepsy in mice lacking 5-HT2C serotonin receptors , 1995, Nature.

[74]  P. Soubrié,et al.  SR141716A, a potent and selective antagonist of the brain cannabinoid receptor , 1994, FEBS letters.

[75]  D. Kaiser,et al.  Effects of long‐term therapy with naltrexone on body weight in obesity , 1985, Clinical pharmacology and therapeutics.

[76]  S. Holtzman.  Behavioral effects of separate and combined administration of naloxone and d-amphetamine. , 1974, The Journal of pharmacology and experimental therapeutics.

[77]  F. Barth.  CB1 Cannabinoid Receptor Antagonists , 2005 .

[78]  Mark D. McBriar,et al.  Melanin-Concentrating Hormone as a Therapeutic Target , 2005 .

[79]  R. Aslanian,et al.  Recent Progress in Histamine H3 Receptor Chemistry , 2004 .

[80]  A. Stamford,et al.  Chapter 7. Recent developments in neuropeptide Y receptor modulators , 2003 .

[81]  B. Eastwood,et al.  Peptides that regulate food intake: antagonism of opioid receptors reduces body fat in obese rats by decreasing food intake and stimulating lipid utilization. , 2003, American journal of physiology. Regulatory, integrative and comparative physiology.

[82]  P. O'Neil,et al.  A controlled trial of naltrexone in obese humans. , 1985, International journal of obesity.